Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
CTLT.US
id: 592

Catalent (CTLT) Misleading Case

D. New Jersey
Court
23-CV-01108
Case number
30 Aug 2021
Class period Start
31 Oct 2022
Class period End
24 Apr 2023
Lead Plaintiff motion deadline
  • Catalent (CTLT) warned that slow production at its facilities will affect 2023 results.
  • CFO Thomas Castellano has stepped down.
  • $CTLT lost over 26%. and $3B of MCap.
  • Investors suspect Catalent & its Leaders of financial misrepresentation and misleading on business prospects.
On April 14, 2023, Catalent (CTLT), a contract drug manufacturer, warned that slow production at three of its facilities will affect its fiscal 2023 results. CFO Thomas Castellano has stepped down.

On this news, $CTLT dropped over 26%, injuring investors.

On November 1, 2022, Catalent (CTLT) revealed that its quarterly earnings had declined to zero and lowered its financial guidance, indicating falling demand.

The Company also disclosed that regulatory issues at its key facilities were negatively impacting its financial results.

On this news, Catalent's (CTLT) stock price declined over 31.7% over two trading sessions, seriously damaging Investors.
  • Later, on November 16, 2022, Catalent (CTLT) revealed that it was carrying approx. $400 million in excess inventory, further revealing that the Company had misrepresented demand for its products as well as its purported ability to predict future demand. On this news, Catalent’s stock price declined by 8.5%.
  • Then, on December 8, 2022, GlassHouse Research published a report claiming that Catalent had been materially overstating its revenues by $568.2 million in violation of GAAP. The report detailed numerous red flags that were indicative of Catalent’s improper accounting practices.
Taking all representations and appeared facts into account, Investors have reasons to suspect the Company and its Leaders of multiple misleading statements, that led to financial damage to shareholders.
Alleged Offence
Misleading Statements
Financial Misrepresentation
Fraud
Failure to Disclose
Malpractice
Negligence
Breach of Fiduciary duty
Omissions
Suspected Party
Directors
Management
Shareholder
Investment Bank
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
14 April 2023
Filing date
24 February 2023
Lead Plaintiff Deadline
24 April 2023
Judge
Hon. Zahid N. Quraishi
Collecting participants…

Catalent Inc

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates ...

    Ticker
    CTLT.US
    ISIN
    US1488061029
    CIK
    1596783
    Sector
    Healthcare
    Industry
    Drug Manufacturers - Specialty & Generic
    Country
    USA
    Address
    14 Schoolhouse Road, Somerset, NJ, United States, 08873